Introduction
Bone formation and remodeling are lifelong biological events that are of paramount importance to maintain the volume, density and function of bone tissue. During bone formation and remodeling, osteoprogenitors undergo osteoblastogenesis, which involves a series of sequential cellular and molecular events, including proliferation, differentiation and extracellular matrix mineralization. 1 Osteoblastogenesis is carefully regulated by various factors in the bone microenvironment and is highly sensitive to adverse systemic conditions, such as alcoholism.
Alcoholism is a highly prevalent addiction. In 2015, the estimated prevalence among the adult population was 18.4% for heavy episodic drinking. 2 Alcohol abuse is 
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liu et al associated with more harmful detrimental effects than nicotine use. 3 Chronic alcohol abuse leads to low bone mass, [4] [5] [6] [7] bone fragility and spontaneous fractures. 4, [8] [9] [10] Animal studies showed that alcohol consumption significantly reduces new bone formation 11 and delays osteointegration of implants, 12 possibly by reducing the number and activity of osteoblasts. 13 Alcoholism can also result in compromised osteoinduction, leading to impaired healing of bone defects. 13 Furthermore, prenatal alcohol exposure also significantly affects fetal bone development.
14 However, the mechanisms accounting for these phenomena remain unclarified. A potential mechanism could be that chronic alcohol abuse significantly increases the concentration of all-trans retinoic acid (ATRA), 15 a metabolite of alcohol, resulting in compromised osteoblastogenesis. 16 ATRA can control bone differentiation pathways during early organogenesis. 17 ATRA regulates the gene expression via its receptors. There are two families of retinoic acid receptors, RARs and RXRs, each of which has three isotypes (α, β and γ).
To promote bone regeneration for repairing bone defects in patients with alcoholism, one strategy is to adopt potent osteoinductive growth factors, such as bone morphogenetic proteins (BMPs). BMPs comprise a group of disulfide bondlinked dimeric proteins and belong to the superfamily of transforming growth factor-β. BMPs, particularly BMP-2 and BMP-7 in absorbable collagen sponge, have been approved by the FDA for promoting bone regeneration in clinical settings. 18, 19 BMP ligands bind to transmembrane BMP receptors, resulting in enhanced levels of phosphorylated Smad1/5 (p-Smad1/5). P-mad1/5 forms a complex with Smad4 and translocates into the nucleus to induce the expression of Dlx5.
20 Dlx5 upregulates two critical osteogenic genes: Runx2 21 and Osterix. 22 BMPs facilitate osteoblastogenic cellular events, such as collagen secretion, differentiation (indicated by the expression of ALP and OCN) and mineralization of extracellular matrix. 23, 24 BMP2 and BMP7, in combination with carriers, have been approved for clinical application to accelerate and enhance bone regeneration and implant osteointegration. 18 However, the clinical doses of homodimeric BMPs are extremely high (eg, up to milligrams), 25, 26 and not only lead to a heavy economic burden on patients, but also can induce a series of potential side effects, including overstimulated osteoclastic activity and ectopic bone formation. 27, 28 One potential solution is to use heterodimeric BMP to stimulate osteoblastogenesis. Heterodimeric BMP is more potent than homodimeric BMP; we previously demonstrated that heterodimeric BMP2/7 induced osteoblastogenesis at significantly lower optimal concentrations than homodimeric BMPs. 23 In an in vivo peri-implant bone defect model, we reported that low-dose BMP2/7 heterodimer facilitated more rapid and better quality bone regeneration than homodimeric BMPs. 29 Thereafter, we explored the utility of BMPs to promote osteoblastogenesis in alcoholic patients, and we demonstrated that heterodimeric BMP2/7 antagonized the inhibitory effect of ATRA and could rescue osteoblastogenesis. 30, 31 However, it remains unclear whether the more potent heterodimeric BMP2/7 is superior to homodimeric BMP2 or BMP7 in antagonizing ATRA and promoting osteoblastogenesis. In this study, we aimed to compare the effects of BMP2/7 heterodimer to those of BMP2 and BMP7 homodimers in promoting osteoblastogenesis in the presence of 1 µM ATRA. We used a murine calvaria-derived cell line (MC3T3-E1), one of the most convenient and physiologically relevant model systems to study bone regeneration.
32 MC3T3-E1 cell line is also one of most frequently adopted cell model to investigate the effect of ATRA on osteoblastogenesis. 33 Our ultimate objective is to choose the more effective BMPs that have potential for facilitating bone regeneration and implanting osteointegration for patients with excessive alcohol consumption.
Materials and methods study design
We assessed the stimulatory effect of 50 ng/mL BMP2/7 heterodimer, BMP2 homodimer or BMP7 homodimer on osteoblastogenesis of preosteoblasts in the presence or absence of 1 µM ATRA. The concentration of BMP was based on our previous studies. 23 In addition, 1 µM ATRA was regularly used to study the in vitro effects of ATRA on osteogenic differentiation. 34, 35 We evaluated osteoblastogenesis by gauging cell viability, ALP activity (as a marker of early stage differentiation), OCN (as a marker of late-stage differentiation) and cellular matrix mineralized nodules (as the marker of final differentiation), as well as expression of key genes involved in osteoblastogenesis-related signaling pathways, including Smad1, Dlx5, Runx2 and Osterix. 
cell viability assay
Cell viability and proliferation of each group were determined using the AlamarBlue ® cell viability reagent (Invitrogen Corporation, Carlsbad, CA, USA) after treatment with BMPs for 1 day, 4 days and 7 days. Fluorescence intensity was measured using a fluorescent spectrometer (SpectraMax M5 Molecular Devices, Sunnyvale, CA, USA) at EX 540 nm/ EM 590 nm.
alP activity assay
Early osteogenic differentiation of preosteoblasts was assessed by assessing ALP activity assay. ALP activity and total protein content were measured after treatment with BMPs for 4 days and 7 days. The ALP activity in the cell lysate (Sigma-Aldrich) was determined using LabAssay™ ALP colorimetric assay kit (Wako Pure Chemicals, Osaka, Japan). The total protein content was measured at 570 nm using a commercial BCA Protein Assay kit (Beyotime, Shanghai, China). Values were expressed as nmol p-NP/µg total protein/hour to indicate the ALP activity.
Ocn expression assay
OCN secreted into cell culture medium was determined to assess the terminal differentiation of preosteoblasts. Cell supernatants were collected and centrifuged (10,000 rpm, 4°C, 5 minutes) on day 4 and day 7 before analysis. The OCN concentration was determined by ELISA using a mouse OCN EIA kit (Biomedical Technologies, Stoughton, MA, USA). 23, 36 alizarin red staining Alizarin red staining was used to assess the final mineralized nodules in each group. We compared the area of mineralized nodules in samples stimulated with BMP2/7, BMP2, BMP7 and/or ATRA. MC3T3-E1 cells were treated in the same way as described previously 37 and then treated with mineralizing medium (10% FBS, 50 µg/mL L-ascorbic acid and 10 mM β-glycerophosphate; Sigma-Aldrich) containing BMP2/7 and/or ATRA. The medium was replaced every 3 days. On day 21 and day 28, mineralized nodules were determined by alizarin red staining (Sigma-Aldrich), as previously described. 37 Culture plates were photographed by NIS-Elements F2.20 (Nikon Eclipse 80i, Tokyo, Japan), and the calcified areas were then quantified using Image-Pro Plus 6.0 software.
isolation of total rna and real-time fluorescence quantitative PCR (RT-qPCR) analysis
Total RNA was extracted from the cells treated with BMPs and/or ATRA using an RNeasy Mini Kit and purified with RNase-Free DNase Set reagent (Qiagen, Hilden, Germany), following the manufacturer's instructions, on day 4 and day 7. Total RNA was reverse transcribed to cDNA using a PrimeScript ® RT Master Mix kit (Perfect Real Time, Takara, Tokyo, Japan). RT-qPCR was performed using a PrimeScript ® RT reagent kit (Perfect Real Time, Takara), according to the manufacturer's instruction. Specific primers used for detecting mRNA transcripts of the ALP, OCN, Collagen I, Runx2, Dlx5, Osterix, Smad1 and β-actin genes are shown in Table 1 . Gene expression was normalized to the β-actin transcript levels. The n-fold upregulation for each gene of interest was calculated over the internal control gene (β-actin gene) according to the ΔΔCt method using the formula: 2-[(CT gene of interest-CTinternal control) sample-(CT gene of interest-CT internal control) control]. 38 
statistical analysis
All data are presented as mean ± SD. Comparisons between groups were made by one-way ANOVA. Post hoc comparisons were made using Bonferroni corrections. The level of significance was set at P,0.05. SPSS software (version 20) for a Windows computer system was used for statistical analysis.
Results

cell viability
The cell viability in each group was determined by the AlamarBlue ® Cell Viability Assay. On day 1, neither ATRA nor BMPs showed a significant effect on the viability of preosteoblasts (Figure 1 ). On day 4 and day 7, treatment with 1 µM ATRA resulted in significant reduction of cell viability compared to the control (no BMP, no ATRA). Notes: 1) no aTra, no BMPs (c); 2) 1 µM aTra, no BMPs (a); 3) no aTra, 50 ng/ml BMP2/7 (27); 4) 1 µM aTra, 50 ng/ml BMP2/7 (27a); 5) no aTra, 50 ng/ml BMP2 (2); 6) 1 µM aTra, 50 ng/ml BMP2 (2a); 7) no aTra, 50 ng/ml BMP7 (7); 8) 1 µM aTra, 50 ng/ml BMP7 (7a) for 1 day, 4 days and 7 days. all data are presented as mean values together with the standard deviation (sD). *p,0.05, **p,0.01, ***p,0.001. Abbreviation: ns, not significant. On day 4 and day 7, treatment with each BMP alone was able to induce higher ALP activities than the control (no BMP, no ATRA; Figure 2 ). Treatment with BMP2/7 alone induced higher ALP activities than BMP2 or BMP7. On both day 4 and day 7, treatment with ATRA did not significantly influence ALP activity, regardless of the presence or absence of the various BMP treatments.
Ocn expression
On both day 4 and day 7, treatment with BMP2/7, BMP2 or BMP7 induced higher OCN expression than control (no BMP, no ATRA; Figure 3 ). Treatment with BMP2/7 alone induced higher OCN expression than BMP2 or BMP7 on day 4 and day 7. By contrast, treatment with ATRA significantly decreased OCN expression both in the absence of BMPs and in the presence of BMP2/7 and BMP7. The reduction in OCN expression resulting from treatment with ATRA was restored to a similar level as the control by treatment with all the BMPs. Interestingly, on day 7, OCN expression in the BMP2/7 + ATRA treatment group was significantly lower than in the groups treated with BMP2 or BMP7 alone with the addition of ATRA.
evaluation of cellular matrix mineralized nodules
On both day 21 and day 28, treatment with BMP2/7, BMP2, or BMP7 induced a greater number of mineralized nodules than the control (no BMP, no ATRA; Figure 4) . Furthermore, treatment with BMP2/7 alone significantly induced a greater number of mineralized nodules than BMP2 or BMP7 at both time points. In contrast, treatment with ATRA significantly decreased production of cell matrix mineralized nodules both in the absence and in the presence of BMPs. Treatment with all three BMPs was able to rescue the formation of mineralized nodules that was inhibited by ATRA to a level that was similar to the control. In this capacity, treatment Figure 2 The activity of alkaline phosphatase (alP) of murine calvarial pre-osteoblasts (Mc3T3-e1 cells) under the different treatments. Notes: 1) no aTra, no BMPs (c); 2) 1 µM aTra, no BMPs (a); 3) no aTra, 50 ng/ml BMP2/7 (27); 4) 1 µM aTra, 50 ng/ml BMP2/7 (27a); 5) no aTra, 50 ng/ml BMP2 (2); 6) 1 µM aTra, 50 ng/ml BMP2 (2a); 7) no aTra, 50 ng/ml BMP7 (7); 8) 1 µM aTra, 50 ng/ml BMP7 (7a) after for 4 day and 7 days. The alP activity was normalized to total cellular protein content. all data are presented as mean values together with the standard deviation (sD). *p,0.05, **p,0.01, ***p,0.001. Abbreviation: ns, not significant. Figure 3 The expression of osteocalcin (Ocn) of murine calvarial pre-osteoblasts (Mc3T3-e1) under the different treatments. Notes: 1) no aTra, no BMPs; 2) 1 µM aTra, no BMPs; 3) no aTra, 50 ng/ml BMP2/7; 4) 1 µM aTra, 50 ng/ml BMP2/7; 5) no aTra, 50 ng/ml BMP2; 6) 1 µM aTra, 50 ng/ml BMP2; 7) no aTra, 50 ng/ml BMP7; 8) 1 µM aTra, 50 ng/ml BMP7 for 4 days and 7 days. all data are presented as mean values together with the standard deviation (sD). *p,0.05, **p,0.01, ***p,0.001. 
expression of osteogenic differentiation marker genes
On both day 4 and day 7, treatment with BMP2/7 alone induced significantly higher expression of Collagen Iα than the control or treatment with either homodimeric BMP ( Figure 5 ). Treatment with ATRA was able to significantly suppress the expression both in the absence or presence of all BMPs. On day 7, ATRA suppressed expression of Collagen Iα to a significantly lower than the control, even in the presence of any of the three BMPs. The gene expression patterns of ALP and OCN were consistent with their protein expression. Treatment with ATRA significantly affected the expression of OCN, but not ALP. On day 7, BMP2/7 did not show any advantage over BMP2 or BMP7 in enhancing OCN gene expression in the presence of ATRA.
expression of BMP signaling key genes
Dlx5 gene expression was significantly enhanced by treatment with BMP2/7 on day 4 and day 7, and was enhanced by treatment with BMP2 on day 4 ( Figure 6 ). Treatment with ATRA significantly downregulated Dlx5 gene expression in both the absence of BMPs and in the presence of BMP2/7. However, ATRA treatment did not significantly influence Dlx5 expression in the presence of BMP2 and BMP7. BMP2/7 without ATRA could significantly increase Runx2 Figure 4 The mineralization of murine calvarial pre-osteoblasts (M3T3e1-e1) under the different treatment. (above) light micrographs depicting the mineralization (alizarin red staining) of murine calvarial pre-osteoblasts (Mc3T3-e1 cells) under the different treatments. Notes: 1) no aTra, no BMPs (c); 2) 1 µM aTra, no BMPs (a); 3) no aTra, 50 ng/ml BMP2/7 (27); 4) 1 µM aTra, 50 ng/ml BMP2/7 (27a); 5) no aTra, 50 ng/ml BMP2 (2); 6) 1 µM aTra, 50 ng/ml BMP2 (2a); 7) no aTra, 50 ng/ml BMP7 (7); 8) 1 µM ATRA, 50 ng/mL BMP7 (7a) for 21 days and 28 days. (Below) Graph depicting the calcification area of murine calvarial pre-osteoblasts (Mc3T3-e1 cells) per well under the different treatments: 1) no aTra, no BMPs (c); 2) 1 µM aTra, no BMPs (a); 3) no aTra, 50 ng/ml BMP2/7 (27); 4) 1 µM aTra, 50 ng/ml BMP2/7 (27a); 5) no aTra, 50 ng/ml BMP2 (2); 6) 1 µM aTra, 50 ng/ml BMP2 (2a); 7) no aTra, 50 ng/ml BMP7 (7) gene expression compared to control group. On day 4 and day 7, treatment with ATRA significantly affected Runx2 gene expression induced by BMP2/7, but not by BMP2 or BMP7. In the presence of ATRA, treatment with BMP2/7 did not induce higher expression of Runx2 than BMP2. Except for BMP7 on day 7, treatment with all BMPs induced a similar level of Runx2 gene expression, which was significantly higher than the ATRA group on day 4 and day 7.
At both time points, treatment with BMP2/7 and BMP2 induced a significant increase in Osterix gene expression.
Figure 5
The relative gene expression of osteogenic differentiation marker genes under the different treatment. Notes: graph depicting the relative expression of (a) collagen i, (b) alkaline phosphatase and (c) Osteocalcin genes expression under the different treatments: under the different treatments: 1) no aTra, no BMPs (c); 2) 1 µM aTra, no BMPs (a); 3) no aTra, 50 ng/ml BMP2/7 (27); 4) 1 µM aTra, 50 ng/ml BMP2/7 (27a); 5) no aTra, 50 ng/ml BMP2 (2); 6) 1 µM aTra, 50 ng/ml BMP2 (2a); 7) no aTra, 50 ng/ml BMP7 (7); 8) 1 µM aTra, 50 ng/ml BMP7 (7a) for 4 days and 7 days. The gene expression was first normalized to the corresponding β-actin gene expression for each sample. Then all the gene data were normalized to the gene data in control group on day 4. all data are presented as mean values together with the standard deviation (sD). *p,0.05, **p,0.01, ***p,0.001. On day 4, all the three BMPs induced significant increases in Smad1 gene expression. ATRA significantly reduced the increase of Smad1 gene expression due to BMP7 treatment.
On day 7, BMP2/7 and BMP2 induced a 5.8-and 3.3-fold increase in Smad1 gene expression compared to the control, respectively. ATRA significantly suppressed the Smad1 gene expression induced by BMP2/7 and BMP7, but not Smad1 gene expression induced by BMP2. In the presence of ATRA, all three BMPs induced a significant increase in Smad1 gene expression over treatment with ATRA alone. 
Discussion
The restoration of large bone defects is very challenging, especially for patients with adverse systemic conditions, such as alcoholism. Animal studies demonstrate that chronic alcohol abuse can lead to substantial increases in ATRA concentration of various organ systems. 15 High concentrations of ATRA are regarded as important mediators for alcoholism-related osteoporosis 10 and compromised osteogenesis. 11 In our previous studies, we demonstrated that heterodimeric BMP2/7 was able to antagonize the inhibitive effect of ATRA and rescue in vitro osteoblastogenesis of immortalized preosteoblast cells 31 and primary BMSCs. 30 In this study, we, for the first time, compared the efficacy of heterodimeric BMP2/7 and homodimeric BMPs in antagonizing such effects of ATRA. In the presence of ATRA, BMP2/7 still induced significantly higher cell viability and early differentiation than the homodimers. However, ATRA significantly attenuated the advantages of BMP2/7 in inducing late and final osteoblastogenic differentiation over the homodimers. ATRA-inhibited osteoblastogenesis was previously characterized as a partially differentiated non-proliferating state. 39 These characteristics are based on the findings from our own research and other studies demonstrating that ATRA suppresses cell proliferation/viability, OCN expression and formation of mineralized nodules of osteoblasts, but does not influence or promote ALP activity of MC3T3-E1 preosteoblasts 31, 39 or primary mouse BMSCs. 16, 30 Our results demonstrated that the inhibitive effect of ATRA on cell viability did not occur immediately after treatment.
One potential mechanism is that ATRA binds to and inhibits adenine nucleotide translocase, thereby inducing mitochondrial permeability transition through obscure mechanisms. 40 ATRA is shown to promote ALP activity in C3H10T1/2 MSCs 41,42 and the rat preosteoblast cell line, UMR-201-10B, 43 whereas suppresses gene expression of Osterix and OCN in C3H10T1/2 cells. 42 On the other hand, ATRA is also shown to suppress adipogenic differentiation and to promote the osteogenic differentiation of adipose-derived stromal cells or of partially differentiated preadipocytes. 44, 45 These findings suggest a complicated role for ATRA in osteoblastogenesis. It is suggested that the different roles of ATRA are associated with its concentrations: ATRA at high concentrations promotes osteogenic differentiation, whereas ATRA at low concentrations can inhibit osteogenic differentiation. 33 However, the dose-dependent mechanisms do not adequately explain the phenomena observed in the previous studies. It is important to note that a large number of the studies used ALP activity and gene expression as markers for osteogenic differentiation. However, ALP activity is only a marker of early osteogenic differentiation, and enhanced ALP activity does not necessarily lead to the late and final osteogenic differentiation. Furthermore, the promoting effect of ATRA on ALP gene expression is not through the classic osteogenic signaling pathways, such as promoting endogenous BMPs. Instead, this effect of ATRA is shown to be highly dependent on a retinoid acid response element in the promoter of the ALP gene. 42 RA-induced osteogenic differentiation of ADAS seems to be dependent on RA-induced TGF-β signaling, wherein it is demonstrated Figure 6 The relative gene expression of BMP signaling key genes under the different treatment. Notes: graph depicting the relative expression of (a) Dlx5, (b) runx2, (c) Osterix and (d) smad1 genes expression under the different treatments: under the different treatments: 1) no aTra, no BMPs (c); 2) 1 µM aTra, no BMPs (a) ; 3) no aTra, 50 ng/ml BMP2/7 (27) ; 4) 1 µM aTra, 50 ng/ml BMP2/7 (27a); 5) no aTra, 50 ng/ml BMP2 (2); 6) 1 µM aTra, 50 ng/ml BMP2 (2a); 7) no aTra, 50 ng/ml BMP7 (7); 8) 1 µM ATRA, 50 ng/mL BMP7 (7a) for 4 days and 7 days. The gene expression was first normalized to the corresponding β-actin gene expression for each sample. Then all the gene data were normalized to the gene data in control group on day 4. all data are presented as mean values together with the standard deviation (sD). *p,0.05, **p,0.01, ***p,0.001. that RA enhances the endogenous expression of TGF-β1 and TGF-β2. 41 Furthermore, ATRA enhances the endogenous expression of Smad3, a key transcription factor involved in TGF-β signaling, thereby initiating the displacement of a negative regulatory transcription factor CCAAT/EBPβ, from the Runx2 promoter. 46 On the other hand, TGF-β is also shown to inhibit BMP-2 induced osteoblastogenesis. 20 All these molecular events may be accounted for the complicated and ambiguous effects of ATRA on osteoblastogenesis in different cell types.
During natural skeletal development, Runx2 is an upstream regulator of Osterix and Dlx5 expression. By contrast, during BMP-induced osteoblastogenesis, BMPtriggered p-Smad1/5 directly upregulates Dlx5, which is an upstream regulator that is independently able to regulate both Runx2 and Osterix. 47 In this study, we, for the first time, showed that heterodimeric BMP2/7 induced significantly higher expression of Dlx5 than homodimeric BMP2 or BMP7. Consistently, BMP2/7 induced significantly higher Smad1/5 gene expression than the homodimeric BMPs at a later time point, suggesting a positive feedback regulation. The subsequent increase in Runx2 gene expression induced by BMP2/7 was significantly higher than that induced by BMP7 on day 4, and was also higher than Runx2 expression induced by both BMP2 and BMP7 on day 7. The BMP2/7-induced expression of Osterix was higher than that induced by BMP2, and significantly higher than that induced by BMP7. These data indicated that BMP2/7 treatment induced higher activation of canonical signaling pathways and positive feedback signaling than BMP2 and BMP7 at the same concentration. Our data also showed that BMP2/7 triggered significantly higher activation of p-Smad1/5 than BMP2 (data not shown), which indirectly supported the hypothesis that the higher potency of BMP2/7 might be attributed to a significantly higher binding affinity to both type I and type II receptors than the homodimers. 48 In comparison with ATRA alone, all the three BMPs could significantly rescue the late differentiation marker, OCN, and the final differentiation marker, mineralized nodules. Nevertheless, ATRA significantly suppressed OCN and mineralization, regardless of the potency of the different BMPs. Interestingly, the extent of the suppressive effect of ATRA did not correlate to the potency of BMPs. It seemed that ATRA was able to generalize the effect of BMPs, reduce the expression of OCN and impair the formation of mineralized nodules to a similar level as that of the control group. In contrast to BMP2 and BMP7, BMP9 is a special BMP that triggers both Smad1/5 and Smad2/3 to promote osteoblastogenesis. 49 Zhang et al showed that ATRA can significantly potentiate BMP9-induced osteoblastogenesis. 50 These contradictory findings underline the complicated and ambiguous modulation machinery of ATRA in osteoblastogenesis.
Hitherto, how BMPs and ATRA interact with each other in the process of osteoblastogenesis remains largely unknown. One study in embryonic stem cells suggested a potential mechanism for such an effect of ATRA: the signal duration of p-Smad1/5 is significantly affected by ATRA by promoting Gadd45 and MAPK-mediated ubiquitination and proteasomal degradation of p-Smad1/5. 35 However, our data did not demonstrate that the duration of p-Smad1/5 activation was significantly compromised by ATRA in MC3T3-E1 preosteoblasts (data not shown).
In conclusion, although BMP2/7 was more potent in promoting osteoblastogenesis, BMP2/7 was not superior to homodimeric BMPs in antagonizing the inhibitive effects of ATRA on osteoblastogenesis. ATRA might affect BMP-induced osteoblastogenesis through a series of molecular mechanisms, including suppression of Dlx5 gene transcription. One of the limitations of this study was that we only used a murine-derived preosteoblast cell line. Although the MC3T3-E1 cell line has been frequently used to investigate the effects of BMP, ATRA and their combination on osteoblastic differentiation, current results should be validated in primary cells before being used to extrapolate in vivo mechanisms. Furthermore, a pertinent in vivo study is needed to show the interaction of ATRA and different BMPs in modulating in vivo bone regeneration.
